Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1 Effect After Gastric Bypass
NCT02287285Phase 1Completed
- Start
- Oct 2014
- Primary completion
- Aug 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of exendin 9-39 in type 2 diabetes mellitus (T2DM). Primary endpoint: Beta Cell Sensitivity (BCS). Started Oct 2014; status: completed.
02
Drugs
exendin 9-39
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02287285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287285.